DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (NCT06953089)
A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Who can join: Review the eligibility criteria below.
Location: USA06-0 — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- USA06-0 — Los Angeles, California
- USA16-0 — Los Angeles, California
- USA01-0 — Wheat Ridge, Colorado
- USA08-0 — Florida City, Florida
- USA10-0 — Atlanta, Georgia
- USA11-0 — Bethesda, Maryland
- USA14-0 — Lincoln, Nebraska
- USA04-0 — New York, New York
- USA15-0 — Portland, Oregon
- USA03-0 — Charleston, South Carolina
- USA13-0 — Anderson, Texas
- USA12-0 — Houston, Texas
- USA05-0 — Virginia Beach, Virginia
- USA09-0 — Puyallup, Washington
- USA07-0 — Spokane, Washington
- AUS07-0 — North Sydney, New South Wales
- AUS06-0 — Benowa, Queensland
- AUS04-0 — Birtinya, Queensland
- AUS05-0 — Adelaide, South Australia
- CHN02-0 — Beijing, Beijing Municipality
- CHN13-0 — Beijing, Beijing Municipality
- CHN23-0 — Beijing, Beijing Municipality
- CHN17-0 — Dongguan, Guangdong
- CHN06-0 — Henan, Henan
- CHN12-0 — Xinxiang, Henan
📞 Contact the Study Coordinator
Phone: (540) 808-3925
Email: jay.ma@dualitybiologics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.